MCID: PDT042
MIFTS: 50

Pediatric Hepatocellular Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Pediatric Hepatocellular Carcinoma

MalaCards integrated aliases for Pediatric Hepatocellular Carcinoma:

Name: Pediatric Hepatocellular Carcinoma 12 20 15
Childhood Hepatocellular Carcinoma 12 20 29 6 70
Childhood Carcinoma of Liver Cell 20
Pediatric Carcinoma of Liver Cell 20
Childhood Liver Cell Carcinoma 20
Pediatric Liver Cell Carcinoma 20
Childhood Liver Cancer 70
Childhood Hepatoma 20
Pediatric Hepatoma 20

Classifications:



External Ids:

Disease Ontology 12 DOID:0070322
NCIt 50 C7955
UMLS 70 C0279606 C2945767

Summaries for Pediatric Hepatocellular Carcinoma

GARD : 20 Childhood hepatocellular carcinoma (childhood HCC) is a rare type of malignant (cancerous) tumor that forms in the cells and tissues of the liver. Childhood HCC is usually found in older children and adolescents (10-14 years), but has been found in children younger than 5. Symptoms may include a mass in the abdomen, a swollen and painful abdomen, weight loss, poor appetite, yellowing of the skin and eyes ( jaundice ), vomiting, fever, itchy skin, and a decreased number of red blood cells ( anemia ). The cause of childhood HCC is not well understood; however, underlying disorders that cause liver dysfunction (ex. hepatitis B ) and congenital or genetic disorders that affect the liver (ex. tyrosinemia type 1 ) may increase the risk for childhood HCC to occur. Treatment options vary depending on a variety of factors including the stage of the cancer and may include surgery to remove the tumor and chemotherapy.

MalaCards based summary : Pediatric Hepatocellular Carcinoma, also known as childhood hepatocellular carcinoma, is related to cholangiocarcinoma and hepatoblastoma, and has symptoms including fever, abdominal pain and icterus. An important gene associated with Pediatric Hepatocellular Carcinoma is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are MET promotes cell motility and Proteoglycans in cancer. The drugs Doxorubicin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include liver and thyroid, and related phenotypes are hepatomegaly and hepatic fibrosis

Disease Ontology : 12 A hepatocellular carcinoma that occurs in children and is characterized by a distinct etiological predisposition, biological behavior, and lower frequency of cirrhosis as compared to adult hepatocellular carcinoma.

Related Diseases for Pediatric Hepatocellular Carcinoma

Graphical network of the top 20 diseases related to Pediatric Hepatocellular Carcinoma:



Diseases related to Pediatric Hepatocellular Carcinoma

Symptoms & Phenotypes for Pediatric Hepatocellular Carcinoma

Human phenotypes related to Pediatric Hepatocellular Carcinoma:

31 (show all 9)
# Description HPO Frequency HPO Source Accession
1 hepatomegaly 31 hallmark (90%) HP:0002240
2 hepatic fibrosis 31 hallmark (90%) HP:0001395
3 abdominal pain 31 hallmark (90%) HP:0002027
4 elevated alpha-fetoprotein 31 hallmark (90%) HP:0006254
5 vomiting 31 frequent (33%) HP:0002013
6 fatigue 31 frequent (33%) HP:0012378
7 portal vein thrombosis 31 frequent (33%) HP:0030242
8 epigastric pain 31 frequent (33%) HP:0410019
9 hepatic necrosis 31 frequent (33%) HP:0002605

UMLS symptoms related to Pediatric Hepatocellular Carcinoma:


fever; abdominal pain; icterus; malaise

Drugs & Therapeutics for Pediatric Hepatocellular Carcinoma

Drugs for Pediatric Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
2
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
3
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
4
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
5
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 5310940 9887054 43805 6857599
6
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
7
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
8
Sorafenib Approved, Investigational Phase 2, Phase 3 284461-73-0 216239 406563
9
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
10
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
11
Irinotecan Approved, Investigational Phase 2, Phase 3 100286-90-6, 97682-44-5 60838
12 Liver Extracts Phase 2, Phase 3
13 Antibiotics, Antitubercular Phase 2, Phase 3
14
Liposomal doxorubicin Phase 2, Phase 3 31703
15 Anti-Bacterial Agents Phase 2, Phase 3
16 Immunosuppressive Agents Phase 2, Phase 3
17 Immunologic Factors Phase 2, Phase 3
18 Anti-Infective Agents Phase 2, Phase 3
19 Antiviral Agents Phase 2, Phase 3
20 Antimetabolites Phase 2, Phase 3
21 Tubulin Modulators Phase 2, Phase 3
22 topoisomerase I inhibitors Phase 2, Phase 3
23 Etoposide phosphate Phase 2, Phase 3
24 Antimitotic Agents Phase 2, Phase 3
25 Dermatologic Agents Phase 2, Phase 3
26 Keratolytic Agents Phase 2, Phase 3
27 Protein Kinase Inhibitors Phase 2, Phase 3
28 Podophyllotoxin Phase 2, Phase 3 518-28-5
29
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
30
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
31
Sodium citrate Approved, Investigational Phase 2 68-04-2
32
Tamoxifen Approved Phase 2 10540-29-1 2733526
33
Melphalan Approved Phase 2 148-82-3 4053 460612
34
Pembrolizumab Approved Phase 2 1374853-91-4
35
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
36
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
37 Angiogenesis Inhibitors Phase 2
38 Antirheumatic Agents Phase 2
39 Interferon alpha-2 Phase 2
40 interferons Phase 2
41 Interferon-alpha Phase 2
42 Citrate Phase 2
43 Hormone Antagonists Phase 2
44 Estrogens Phase 2
45 Estrogen Receptor Antagonists Phase 2
46 Hormones Phase 2
47 Antineoplastic Agents, Hormonal Phase 2
48 Estrogen Antagonists Phase 2
49 Estrogen Receptor Modulators Phase 2
50 Cola Phase 2

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Liver Tumour Studies - Hepatoblastoma and Hepatocellular Carcinoma Completed NCT00003912 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride
2 Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) Recruiting NCT03533582 Phase 2, Phase 3 Carboplatin;Cisplatin;Doxorubicin;Etoposide;Fluorouracil;Gemcitabine;Irinotecan;Oxaliplatin;Sorafenib;Vincristine Sulfate
3 Hepatocellular Carcinoma Family of Tumours In Children / Adolescents and Young Adults Unknown status NCT00276705 Phase 2 cisplatin;cyclophosphamide;doxorubicin hydrochloride;thalidomide
4 A Phase II Trial of Oxaliplatin/Adriamycin/5 Fluorouracil in Continuous Infusion / Interferon α-2b (OXAFI) Combination as Neoadjuvant Therapy in Unresectable Non-Metastatic Hepatocellular Carcinoma Unknown status NCT00471484 Phase 2 doxorubicin hydrochloride;fluorouracil;oxaliplatin
5 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
6 A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver Completed NCT00019786 Phase 2 isolated perfusion;melphalan
7 A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma Completed NCT01502410 Phase 2 sorafenib tosylate
8 The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates - A Phase II Study Recruiting NCT04134559 Phase 2 Pembrolizumab
9 Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
10 A Pilot Study of Irradiated HLA-Partially Matched Allogeneic Related Donor Lymphocytes for Patients With Selected Malignancies Completed NCT00161187 Phase 1
11 Genetic and Molecular Basis of Pediatric Liver Cancer Recruiting NCT03959800
12 Molecular Analysis of Liver Cancer Withdrawn NCT00899002

Search NIH Clinical Center for Pediatric Hepatocellular Carcinoma

Genetic Tests for Pediatric Hepatocellular Carcinoma

Genetic tests related to Pediatric Hepatocellular Carcinoma:

# Genetic test Affiliating Genes
1 Childhood Hepatocellular Carcinoma 29

Anatomical Context for Pediatric Hepatocellular Carcinoma

MalaCards organs/tissues related to Pediatric Hepatocellular Carcinoma:

40
Liver, Thyroid

Publications for Pediatric Hepatocellular Carcinoma

Articles related to Pediatric Hepatocellular Carcinoma:

(show top 50) (show all 61)
# Title Authors PMID Year
1
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. 6
9927037 1999
2
Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma. 61
33620289 2021
3
Imaging and clinical features of pediatric hepatocellular carcinoma. 61
33751174 2021
4
Transarterial Radioembolization Treatment as a Bridge to Surgical Resection in Pediatric Hepatocellular Carcinoma. 61
33769387 2021
5
Pediatric Hepatocellular Carcinoma. 61
32856229 2020
6
Pediatric Hepatoblastoma, Hepatocellular Carcinoma, and Other Hepatic Neoplasms: Consensus Imaging Recommendations from American College of Radiology Pediatric Liver Reporting and Data System (LI-RADS) Working Group. 61
32602829 2020
7
Sorafenib in pediatric hepatocellular carcinoma from a clinician perspective. 61
32183592 2020
8
Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma. 61
32806748 2020
9
Surgical management of pediatric hepatocellular carcinoma: An analysis of the National Cancer Database. 61
32660779 2020
10
Clinical heterogeneity of pediatric hepatocellular carcinoma. 61
32307899 2020
11
Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations. 61
32189106 2020
12
Hepatoblastoma and Pediatric Hepatocellular Carcinoma: An Update. 61
31554479 2020
13
Hepatitis B Virus Seropositivity Is a Poor Prognostic Factor of Pediatric Hepatocellular Carcinoma: a Population-Based Study in Hong Kong and Singapore. 61
33330043 2020
14
Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation. 61
30977242 2019
15
Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association With Outcomes: Single-center Experience. 61
30676520 2019
16
Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients. 61
30259629 2019
17
Orthotopic Liver Transplantation After Stereotactic Body Radiotherapy for Pediatric Hepatocellular Carcinoma with Central Biliary Obstruction and Nodal Involvement. 61
30648040 2018
18
Pediatric hepatocellular carcinoma. 61
30254403 2018
19
2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). 61
29427028 2018
20
Management of pediatric hepatocellular carcinoma: A multimodal approach. 61
28631359 2017
21
Stereotactic body radiotherapy for pediatric hepatocellular carcinoma with central biliary obstruction. 61
28436210 2017
22
Pediatric hepatocellular carcinoma: challenges and solutions. 61
28144610 2017
23
Pediatric hepatocellular carcinoma in a developing country: Is the etiology changing? 61
27392999 2016
24
Cause and effect: the etiology of pediatric hepatocellular carcinoma and the role for liver transplantation. 61
27726261 2016
25
YAP Subcellular Localization and Hippo Pathway Transcriptome Analysis in Pediatric Hepatocellular Carcinoma. 61
27605415 2016
26
Distinct set of chromosomal aberrations in childhood hepatocellular carcinoma is correlated to hepatitis B virus infection. 61
26837720 2016
27
Comparative Analysis and Functional Characterization of HC-AFW1 Hepatocarcinoma Cells: Cytochrome P450 Expression and Induction by Nuclear Receptor Agonists. 61
26310804 2015
28
Transarterial embolization for pediatric hepatocellular carcinoma with cardiac cirrhosis. 61
26013052 2015
29
Secular trends were considered in the evaluation of universal hepatitis B vaccination in Taiwan. 61
25660961 2015
30
Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma. 61
25447203 2015
31
Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM. 61
24138022 2014
32
Approach to pediatric hepatocellular carcinoma. 61
30992867 2013
33
Radioembolisation for treatment of pediatric hepatocellular carcinoma. 61
23212597 2013
34
MPV17-Related Mitochondrial DNA Maintenance Defect 61
22593919 2012
35
Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. 61
21922643 2012
36
Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma. 61
22666492 2012
37
Pre-S2 deletions of hepatitis B virus and hepatocellular carcinoma in children. 61
19816238 2010
38
In vitro photodynamic therapy in pediatric epithelial liver tumors promoted by hypericin. 61
18949433 2008
39
Living donor liver transplantation for a child with recurrent pediatric adult-type hepatocellular carcinoma. 61
18929873 2008
40
Bcl-2 gene silencing in pediatric epithelial liver tumors. 61
17574594 2008
41
Subcutaneous and intrahepatic growth of human hepatoblastoma in immunodeficient mice. 61
16780998 2006
42
Clinical characteristics and prognosis of pediatric hepatocellular carcinoma. 61
16369702 2006
43
Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. 61
16278421 2005
44
Virchows node: rare presentation of childhood hepatocellular carcinoma. 61
15758545 2005
45
Allelic loss but absence of mutations in the polyspecific transporter gene BWR1A on 11p15.5 in hepatoblastoma. 61
15239143 2004
46
RBMY, a male germ cell-specific RNA-binding protein, activated in human liver cancers and transforms rodent fibroblasts. 61
15184870 2004
47
Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. 61
12540504 2003
48
Adult type vs. Childhood hepatocellular carcinoma--are they the same or different lesions? Biology, natural history, prognosis, and treatment. 61
12228910 2002
49
Cancer epidemiology and control in Taiwan: a brief review. 61
11959880 2002
50
Hepatocellular carcinoma: significance of HBV vertical transmission. 61
9876947 1998

Variations for Pediatric Hepatocellular Carcinoma

ClinVar genetic disease variations for Pediatric Hepatocellular Carcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MET NM_001127500.3(MET):c.3572C>T (p.Thr1191Ile) SNV Pathogenic 13888 rs121913675 GRCh37: 7:116419007-116419007
GRCh38: 7:116778953-116778953
2 MET NM_001127500.3(MET):c.3804G>A (p.Met1268Ile) SNV Pathogenic 13889 rs121913676 GRCh37: 7:116423475-116423475
GRCh38: 7:116783421-116783421
3 MET NM_001127500.3(MET):c.3785A>G (p.Lys1262Arg) SNV Pathogenic 13890 rs121913677 GRCh37: 7:116423456-116423456
GRCh38: 7:116783402-116783402

Cosmic variations for Pediatric Hepatocellular Carcinoma:

9 (show top 50) (show all 15626)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97724722 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 18
2 COSM94430614 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 18
3 COSM94436083 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 18
4 COSM94063771 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 18
5 COSM88264637 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 18
6 COSM102741209 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 18
7 COSM131494492 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.1159A>G p.M387V 22:29049340-29049340 18
8 COSM103081572 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 18
9 COSM95977701 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 18
10 COSM102131817 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 18
11 COSM95960776 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 18
12 COSM113317148 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 18
13 COSM99592496 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 18
14 COSM128686611 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.1072T>A p.F358I 19:36891962-36891962 18
15 COSM123358576 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.691C>T p.L231= 4:145885684-145885684 18
16 COSM123949383 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 18
17 COSM101741672 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 18
18 COSM86004822 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 18
19 COSM98561269 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 18
20 COSM142353152 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 18
21 COSM142221290 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 18
22 COSM99854658 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.156G>A p.V52= 19:52002156-52002156 18
23 COSM139729931 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 18
24 COSM141470046 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 18
25 COSM141819438 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 18
26 COSM145038099 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 18
27 COSM91868668 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 18
28 COSM91880764 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.2171-78T>G p.? 19:30534769-30534769 18
29 COSM140721836 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.2998+205G>A p.? 18:25194955-25194955 18
30 COSM131506983 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 18
31 COSM94799980 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 18
32 COSM90582798 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 18
33 COSM87577038 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 18
34 COSM109096265 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.3433G>T p.V1145L 9:106974156-106974156 18
35 COSM104985080 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.298+23785G>T p.? 2:179745718-179745718 18
36 COSM104427909 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.20G>T p.S7I 2:179745718-179745718 18
37 COSM151538615 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.253+23785G>T p.? 2:179745718-179745718 18
38 COSM127708351 ZNF345 liver,NS,carcinoma,hepatocellular carcinoma c.47-856A>T p.? 19:36891962-36891962 18
39 COSM135887725 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1168C>G p.L390V 16:89734008-89734008 18
40 COSM84511025 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 18
41 COSM111609487 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1444C>G p.L482V 16:89734008-89734008 18
42 COSM92353291 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 18
43 COSM130415812 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.950C>T p.T317I 12:133010889-133010889 18
44 COSM88697750 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 18
45 COSM95253159 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 18
46 COSM94505616 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 18
47 COSM89943752 ZMYM4 liver,NS,carcinoma,hepatocellular carcinoma c.86-8201G>T p.? 1:35350724-35350724 18
48 COSM101398456 ZIC2 liver,NS,carcinoma,hepatocellular carcinoma c.-18C>T p.? 13:99982047-99982047 18
49 COSM113521587 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 18
50 COSM94679661 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 18

Expression for Pediatric Hepatocellular Carcinoma

Search GEO for disease gene expression data for Pediatric Hepatocellular Carcinoma.

Pathways for Pediatric Hepatocellular Carcinoma

GO Terms for Pediatric Hepatocellular Carcinoma

Biological processes related to Pediatric Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.5 PTK2 MET HGF
2 negative regulation of autophagy GO:0010507 9.37 MET HGF
3 positive regulation of protein kinase B signaling GO:0051897 9.33 PTK2 MET HGF
4 positive chemotaxis GO:0050918 9.26 MET HGF
5 hepatocyte growth factor receptor signaling pathway GO:0048012 8.96 MET HGF
6 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 8.62 MET HGF

Sources for Pediatric Hepatocellular Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....